Phenylketonuria (PKU) Cell Models for Research

Phenylketonuria (PKU) is an inherited metabolic disorder caused by mutations in the PAH gene, leading to phenylalanine hydroxylase deficiency. The global incidence is approximately 1 in 10,000-15,000 newborns, with significant variation by region (WHO, 2021). Without early dietary intervention, PKU results in severe intellectual disability, microcephaly, and behavioral problems. Newborn screening programs have dramatically improved outcomes, but lifelong dietary management is required. Untreated PKU leads to irreversible neurological damage, and even treated patients may experience subtle cognitive deficits and psychiatric symptoms. The economic burden includes dietary costs, medical care, and lost productivity, making PKU a significant public health concern.

PKU is an ideal model for studying genotype-phenotype correlations, enzyme deficiency, and metabolic pathways. The PAH gene has over 1,000 known mutations, providing a rich landscape for functional studies. Public datasets, such as the PAHvdb (PAH variation database) and ClinVar, offer extensive mutation data. Open questions include the molecular basis of variable clinical severity, the role of non-PAH modifiers, and the development of novel therapies beyond dietary restriction. Gene-edited cell models are crucial for dissecting these mechanisms and testing new treatments.

While PKU is not a cancer, it involves a metabolic pathway defect. The primary pathway is phenylalanine catabolism:

1. Phenylalanine is hydroxylated to tyrosine by phenylalanine hydroxylase (PAH) in the liver.

2. This reaction requires the cofactor tetrahydrobiopterin (BH4) and molecular oxygen.

3. Deficiency of PAH leads to accumulation of phenylalanine in blood and tissues.

4. Elevated phenylalanine is converted to phenylpyruvate, phenyllactate, and phenylacetate, which are neurotoxic.

5. Tyrosine becomes an essential amino acid, leading to reduced melanin and neurotransmitter synthesis.

These metabolic disturbances affect brain development and function.

Data from ClinVar and PAHvdb. The most common mutation in Northern Europeans is c.1222C>T (p.Arg408Trp), which causes severe PKU.

PKU affects multiple signaling pathways due to neurotransmitter deficiencies:

• • Dopamine synthesis: Tyrosine is a precursor; reduced tyrosine leads to decreased dopamine, affecting motor control and cognition.
• • Serotonin synthesis: Tryptophan hydroxylase requires BH4; BH4 deficiency impairs serotonin production, contributing to mood disorders.
• • Nitric oxide signaling: BH4 is a cofactor for nitric oxide synthase; deficiency may affect vascular function.
• • Myelination: Elevated phenylalanine inhibits oligodendrocyte function, leading to white matter abnormalities.

These networks are interconnected and contribute to the neurological phenotype.

Organoids derived from patient iPSCs can recapitulate liver metabolism and are useful for studying PAH mutations in a 3D context.

• • PAH-deficient mouse models (e.g., PAHenu2) are the most common, with a missense mutation (p.Phe263Ser) causing hyperphenylalaninemia.
• • Genetically engineered mouse models (GEMMs) with targeted PAH knockouts have been developed.
• • Rat models with chemically induced PAH deficiency are also used.
• • No PDX models exist for PKU since it is not a cancer.

These models are used to test dietary interventions, gene therapy, and enzyme replacement.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific PAH mutations. For example:

• • PAH knockout cell lines: Complete loss of PAH function, mimicking severe PKU.
• • PAH point-mutation knock-in lines: Introduction of common mutations like p.Arg408Trp or p.Phe263Ser to study genotype-phenotype correlations.
• • Reporter lines: PAH promoter-driven fluorescent reporters to monitor gene expression.

These models are commercially available from various sources, sequence-verified, and quality-controlled, accelerating research. They are essential for drug screening, functional studies, and development of gene therapies.

Knockout and knock-in cell lines are used to validate the functional impact of PAH mutations. For example:

• • PAH knockout cells show reduced phenylalanine hydroxylase activity and increased phenylalanine accumulation.
• • Knock-in of a specific mutation allows correlation of enzyme activity with clinical severity.
• • CRISPR screens can identify modifier genes that rescue or exacerbate PAH deficiency.

These models help elucidate the molecular basis of PKU and identify potential therapeutic targets.

Isogenic cell line pairs (wild-type vs. mutant) are used for high-throughput screening of compounds that increase PAH activity or reduce phenylalanine levels. For example:

• • Screening for pharmacological chaperones that stabilize mutant PAH.
• • Testing gene therapy vectors in PAH knockout cells.
• • Assessing the efficacy of phenylalanine ammonia lyase (PAL) enzyme therapy.

These models also allow evaluation of drug resistance mechanisms, such as mutations that affect drug binding.

CRISPR-based synthetic lethality screens can identify genes that are essential in PAH-deficient cells but not in wild-type cells. This can reveal novel biomarkers and therapeutic targets. For example:

• • Genes involved in phenylalanine transport or metabolism.
• • Pathways that compensate for PAH deficiency.
• • Biomarkers for monitoring disease progression or treatment response.

These discoveries can lead to new diagnostic and therapeutic strategies.